DW
Therapeutic Areas
Paratek Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| NUZYRA (omadacycline) | Community-Acquired Bacterial Pneumonia (CABP) | Marketed |
| XHANCE (fluticasone propionate) | Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) | Marketed |
| SEYSARA (sarecycline) | Inflammatory Acne Vulgaris | Marketed |
Leadership Team at Paratek Pharmaceuticals
EL
Evan Loh, M.D.
Chief Executive Officer
AW
Adam Woodrow
President and Chief Commercial Officer
RB
Randy Brenner
Chief Development and Regulatory Officer
KM
Karen McGrath
Chief People Officer
CB
Chris Bostrom
Chief Financial Officer
JL
Jonathan Light
Chief Legal Officer, Corporate Secretary, and Corporate Compliance Officer
DS
Dr. Stuart Levy
Founder